Global Thrombin Market
Global Thrombin Market

Thrombin Comprehensive Study by Type (Bovine Thrombin, Human Thrombin, Recombinant Thrombin), Dosage Form (Powder Form, Solution Form), End User (Hospitals, Diagnostics Centers & Clinics, Ambulatory Surgical Centers, Academics & Research Institutes) Players and Region - Global Market Outlook to 2024

Thrombin Market Segmented into XX Submarkets. | Forecast Years: 2019- 2024  

Oct 2019 Edition 228 Pages 166 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Thrombin Market Scope
Thrombin is a serine protease, an enzyme that, in humans, is encoded by the F2 gene. Thrombin is available in many forms as a hemostatic agent and has been purified from numerous sources and classified according to the plasma used to create it. Thrombin has high growth prospects owing to the rising prevalence of blood clotting disorders and increasing surgical activities.

The market study is being classified by Type (Bovine Thrombin, Human Thrombin and Recombinant Thrombin) and major geographies with country level break-up.

Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Thrombin market throughout the predicted period.

Pfizer (United States), Johnson & Johnson Servicess, Inc. (United States), Octapharma AG (Switzerland), Baxter International Inc. (United States), Bayer AG (Germany), CSL Limited (Australia), Grifols, S.A. (Spain), GE Healthcare (United States) and Hualan Biological (China) are some of the key players profiled in the study.

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Thrombin market by Type, Application and Region.

On the basis of geography, the market of Thrombin has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Market Leaders and their expansionary development strategies
In July 2019, Pfizer Inc. announced the successful completion of its acquisition of Array BioPharma Inc., advancing breakthrough science for the discovery, development, and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need.
In Dec 2018, Baxter International Inc.announced the introduction of the Disposable Curved Applicator, which enhances the delivery experience of its Floseal Hemostatic Matrix product line for procedures in the otolaryngology, head, and neck surgical specialty. Floseal Matrix contains Thrombin made from human plasma.


Market Trend
  • Rising Adoption of Smoking increasing the Prevalence of Thrombosis

Market Drivers
  • Growing Prevalence of Blood Clotting Disorders
  • Growth in the Use of Thrombin due to Adoption of Hemostats in Excessive Bleeding during Surgical Procedure

Opportunities
  • Increasing Surgical Procedure due to Increasing Number of Diseases Worldwide
  • Growth and Advancement in Technology in the Healthcare Industry in Developing Countries

Restraints
  • Starigent Govermanebt Regulation

Challenges
  • Ineffective in Patients who Suffer from Afibrinogenemia


Key Target Audience
Thrombin Suppliers/Distributors, Potential Investors, Healthcare Industry and Research and Development Organisation

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Bovine Thrombin
  • Human Thrombin
  • Recombinant Thrombin
By Dosage Form
  • Powder Form
  • Solution Form

By End User
  • Hospitals
  • Diagnostics Centers & Clinics
  • Ambulatory Surgical Centers
  • Academics & Research Institutes

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Prevalence of Blood Clotting Disorders
      • 3.2.2. Growth in the Use of Thrombin due to Adoption of Hemostats in Excessive Bleeding during Surgical Procedure
    • 3.3. Market Challenges
      • 3.3.1. Ineffective in Patients who Suffer from Afibrinogenemia
    • 3.4. Market Trends
      • 3.4.1. Rising Adoption of Smoking increasing the Prevalence of Thrombosis
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Thrombin, by Type, Dosage Form, End User and Region (value and price ) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Thrombin (Value)
      • 5.2.1. Global Thrombin by: Type (Value)
        • 5.2.1.1. Bovine Thrombin
        • 5.2.1.2. Human Thrombin
        • 5.2.1.3. Recombinant Thrombin
      • 5.2.2. Global Thrombin by: Dosage Form (Value)
        • 5.2.2.1. Powder Form
        • 5.2.2.2. Solution Form
      • 5.2.3. Global Thrombin by: End User (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Diagnostics Centers & Clinics
        • 5.2.3.3. Ambulatory Surgical Centers
        • 5.2.3.4. Academics & Research Institutes
      • 5.2.4. Global Thrombin Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Thrombin (Price)
      • 5.3.1. Global Thrombin by: Type (Price)
  • 6. Thrombin: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Johnson & Johnson Servicess, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Octapharma AG (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Baxter International Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Bayer AG (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. CSL Limited (Australia)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Grifols, S.A. (Spain)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. GE Healthcare (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Hualan Biological (China)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Thrombin Sale, by Type, Dosage Form, End User and Region (value and price ) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Thrombin (Value)
      • 7.2.1. Global Thrombin by: Type (Value)
        • 7.2.1.1. Bovine Thrombin
        • 7.2.1.2. Human Thrombin
        • 7.2.1.3. Recombinant Thrombin
      • 7.2.2. Global Thrombin by: Dosage Form (Value)
        • 7.2.2.1. Powder Form
        • 7.2.2.2. Solution Form
      • 7.2.3. Global Thrombin by: End User (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Diagnostics Centers & Clinics
        • 7.2.3.3. Ambulatory Surgical Centers
        • 7.2.3.4. Academics & Research Institutes
      • 7.2.4. Global Thrombin Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Thrombin (Price)
      • 7.3.1. Global Thrombin by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Thrombin: by Type(USD Million)
  • Table 2. Thrombin Bovine Thrombin , by Region USD Million (2013-2018)
  • Table 3. Thrombin Human Thrombin , by Region USD Million (2013-2018)
  • Table 4. Thrombin Recombinant Thrombin , by Region USD Million (2013-2018)
  • Table 5. Thrombin: by Dosage Form(USD Million)
  • Table 6. Thrombin Powder Form , by Region USD Million (2013-2018)
  • Table 7. Thrombin Solution Form , by Region USD Million (2013-2018)
  • Table 8. Thrombin: by End User(USD Million)
  • Table 9. Thrombin Hospitals , by Region USD Million (2013-2018)
  • Table 10. Thrombin Diagnostics Centers & Clinics , by Region USD Million (2013-2018)
  • Table 11. Thrombin Ambulatory Surgical Centers , by Region USD Million (2013-2018)
  • Table 12. Thrombin Academics & Research Institutes , by Region USD Million (2013-2018)
  • Table 13. South America Thrombin, by Country USD Million (2013-2018)
  • Table 14. South America Thrombin, by Type USD Million (2013-2018)
  • Table 15. South America Thrombin, by Dosage Form USD Million (2013-2018)
  • Table 16. South America Thrombin, by End User USD Million (2013-2018)
  • Table 17. Brazil Thrombin, by Type USD Million (2013-2018)
  • Table 18. Brazil Thrombin, by Dosage Form USD Million (2013-2018)
  • Table 19. Brazil Thrombin, by End User USD Million (2013-2018)
  • Table 20. Argentina Thrombin, by Type USD Million (2013-2018)
  • Table 21. Argentina Thrombin, by Dosage Form USD Million (2013-2018)
  • Table 22. Argentina Thrombin, by End User USD Million (2013-2018)
  • Table 23. Rest of South America Thrombin, by Type USD Million (2013-2018)
  • Table 24. Rest of South America Thrombin, by Dosage Form USD Million (2013-2018)
  • Table 25. Rest of South America Thrombin, by End User USD Million (2013-2018)
  • Table 26. Asia Pacific Thrombin, by Country USD Million (2013-2018)
  • Table 27. Asia Pacific Thrombin, by Type USD Million (2013-2018)
  • Table 28. Asia Pacific Thrombin, by Dosage Form USD Million (2013-2018)
  • Table 29. Asia Pacific Thrombin, by End User USD Million (2013-2018)
  • Table 30. China Thrombin, by Type USD Million (2013-2018)
  • Table 31. China Thrombin, by Dosage Form USD Million (2013-2018)
  • Table 32. China Thrombin, by End User USD Million (2013-2018)
  • Table 33. Japan Thrombin, by Type USD Million (2013-2018)
  • Table 34. Japan Thrombin, by Dosage Form USD Million (2013-2018)
  • Table 35. Japan Thrombin, by End User USD Million (2013-2018)
  • Table 36. India Thrombin, by Type USD Million (2013-2018)
  • Table 37. India Thrombin, by Dosage Form USD Million (2013-2018)
  • Table 38. India Thrombin, by End User USD Million (2013-2018)
  • Table 39. South Korea Thrombin, by Type USD Million (2013-2018)
  • Table 40. South Korea Thrombin, by Dosage Form USD Million (2013-2018)
  • Table 41. South Korea Thrombin, by End User USD Million (2013-2018)
  • Table 42. Taiwan Thrombin, by Type USD Million (2013-2018)
  • Table 43. Taiwan Thrombin, by Dosage Form USD Million (2013-2018)
  • Table 44. Taiwan Thrombin, by End User USD Million (2013-2018)
  • Table 45. Australia Thrombin, by Type USD Million (2013-2018)
  • Table 46. Australia Thrombin, by Dosage Form USD Million (2013-2018)
  • Table 47. Australia Thrombin, by End User USD Million (2013-2018)
  • Table 48. Rest of Asia-Pacific Thrombin, by Type USD Million (2013-2018)
  • Table 49. Rest of Asia-Pacific Thrombin, by Dosage Form USD Million (2013-2018)
  • Table 50. Rest of Asia-Pacific Thrombin, by End User USD Million (2013-2018)
  • Table 51. Europe Thrombin, by Country USD Million (2013-2018)
  • Table 52. Europe Thrombin, by Type USD Million (2013-2018)
  • Table 53. Europe Thrombin, by Dosage Form USD Million (2013-2018)
  • Table 54. Europe Thrombin, by End User USD Million (2013-2018)
  • Table 55. Germany Thrombin, by Type USD Million (2013-2018)
  • Table 56. Germany Thrombin, by Dosage Form USD Million (2013-2018)
  • Table 57. Germany Thrombin, by End User USD Million (2013-2018)
  • Table 58. France Thrombin, by Type USD Million (2013-2018)
  • Table 59. France Thrombin, by Dosage Form USD Million (2013-2018)
  • Table 60. France Thrombin, by End User USD Million (2013-2018)
  • Table 61. Italy Thrombin, by Type USD Million (2013-2018)
  • Table 62. Italy Thrombin, by Dosage Form USD Million (2013-2018)
  • Table 63. Italy Thrombin, by End User USD Million (2013-2018)
  • Table 64. United Kingdom Thrombin, by Type USD Million (2013-2018)
  • Table 65. United Kingdom Thrombin, by Dosage Form USD Million (2013-2018)
  • Table 66. United Kingdom Thrombin, by End User USD Million (2013-2018)
  • Table 67. Netherlands Thrombin, by Type USD Million (2013-2018)
  • Table 68. Netherlands Thrombin, by Dosage Form USD Million (2013-2018)
  • Table 69. Netherlands Thrombin, by End User USD Million (2013-2018)
  • Table 70. Rest of Europe Thrombin, by Type USD Million (2013-2018)
  • Table 71. Rest of Europe Thrombin, by Dosage Form USD Million (2013-2018)
  • Table 72. Rest of Europe Thrombin, by End User USD Million (2013-2018)
  • Table 73. MEA Thrombin, by Country USD Million (2013-2018)
  • Table 74. MEA Thrombin, by Type USD Million (2013-2018)
  • Table 75. MEA Thrombin, by Dosage Form USD Million (2013-2018)
  • Table 76. MEA Thrombin, by End User USD Million (2013-2018)
  • Table 77. Middle East Thrombin, by Type USD Million (2013-2018)
  • Table 78. Middle East Thrombin, by Dosage Form USD Million (2013-2018)
  • Table 79. Middle East Thrombin, by End User USD Million (2013-2018)
  • Table 80. Africa Thrombin, by Type USD Million (2013-2018)
  • Table 81. Africa Thrombin, by Dosage Form USD Million (2013-2018)
  • Table 82. Africa Thrombin, by End User USD Million (2013-2018)
  • Table 83. North America Thrombin, by Country USD Million (2013-2018)
  • Table 84. North America Thrombin, by Type USD Million (2013-2018)
  • Table 85. North America Thrombin, by Dosage Form USD Million (2013-2018)
  • Table 86. North America Thrombin, by End User USD Million (2013-2018)
  • Table 87. United States Thrombin, by Type USD Million (2013-2018)
  • Table 88. United States Thrombin, by Dosage Form USD Million (2013-2018)
  • Table 89. United States Thrombin, by End User USD Million (2013-2018)
  • Table 90. Canada Thrombin, by Type USD Million (2013-2018)
  • Table 91. Canada Thrombin, by Dosage Form USD Million (2013-2018)
  • Table 92. Canada Thrombin, by End User USD Million (2013-2018)
  • Table 93. Mexico Thrombin, by Type USD Million (2013-2018)
  • Table 94. Mexico Thrombin, by Dosage Form USD Million (2013-2018)
  • Table 95. Mexico Thrombin, by End User USD Million (2013-2018)
  • Table 96. Thrombin: by Type(USD/Units)
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Thrombin: by Type(USD Million)
  • Table 107. Thrombin Bovine Thrombin , by Region USD Million (2019-2024)
  • Table 108. Thrombin Human Thrombin , by Region USD Million (2019-2024)
  • Table 109. Thrombin Recombinant Thrombin , by Region USD Million (2019-2024)
  • Table 110. Thrombin: by Dosage Form(USD Million)
  • Table 111. Thrombin Powder Form , by Region USD Million (2019-2024)
  • Table 112. Thrombin Solution Form , by Region USD Million (2019-2024)
  • Table 113. Thrombin: by End User(USD Million)
  • Table 114. Thrombin Hospitals , by Region USD Million (2019-2024)
  • Table 115. Thrombin Diagnostics Centers & Clinics , by Region USD Million (2019-2024)
  • Table 116. Thrombin Ambulatory Surgical Centers , by Region USD Million (2019-2024)
  • Table 117. Thrombin Academics & Research Institutes , by Region USD Million (2019-2024)
  • Table 118. South America Thrombin, by Country USD Million (2019-2024)
  • Table 119. South America Thrombin, by Type USD Million (2019-2024)
  • Table 120. South America Thrombin, by Dosage Form USD Million (2019-2024)
  • Table 121. South America Thrombin, by End User USD Million (2019-2024)
  • Table 122. Brazil Thrombin, by Type USD Million (2019-2024)
  • Table 123. Brazil Thrombin, by Dosage Form USD Million (2019-2024)
  • Table 124. Brazil Thrombin, by End User USD Million (2019-2024)
  • Table 125. Argentina Thrombin, by Type USD Million (2019-2024)
  • Table 126. Argentina Thrombin, by Dosage Form USD Million (2019-2024)
  • Table 127. Argentina Thrombin, by End User USD Million (2019-2024)
  • Table 128. Rest of South America Thrombin, by Type USD Million (2019-2024)
  • Table 129. Rest of South America Thrombin, by Dosage Form USD Million (2019-2024)
  • Table 130. Rest of South America Thrombin, by End User USD Million (2019-2024)
  • Table 131. Asia Pacific Thrombin, by Country USD Million (2019-2024)
  • Table 132. Asia Pacific Thrombin, by Type USD Million (2019-2024)
  • Table 133. Asia Pacific Thrombin, by Dosage Form USD Million (2019-2024)
  • Table 134. Asia Pacific Thrombin, by End User USD Million (2019-2024)
  • Table 135. China Thrombin, by Type USD Million (2019-2024)
  • Table 136. China Thrombin, by Dosage Form USD Million (2019-2024)
  • Table 137. China Thrombin, by End User USD Million (2019-2024)
  • Table 138. Japan Thrombin, by Type USD Million (2019-2024)
  • Table 139. Japan Thrombin, by Dosage Form USD Million (2019-2024)
  • Table 140. Japan Thrombin, by End User USD Million (2019-2024)
  • Table 141. India Thrombin, by Type USD Million (2019-2024)
  • Table 142. India Thrombin, by Dosage Form USD Million (2019-2024)
  • Table 143. India Thrombin, by End User USD Million (2019-2024)
  • Table 144. South Korea Thrombin, by Type USD Million (2019-2024)
  • Table 145. South Korea Thrombin, by Dosage Form USD Million (2019-2024)
  • Table 146. South Korea Thrombin, by End User USD Million (2019-2024)
  • Table 147. Taiwan Thrombin, by Type USD Million (2019-2024)
  • Table 148. Taiwan Thrombin, by Dosage Form USD Million (2019-2024)
  • Table 149. Taiwan Thrombin, by End User USD Million (2019-2024)
  • Table 150. Australia Thrombin, by Type USD Million (2019-2024)
  • Table 151. Australia Thrombin, by Dosage Form USD Million (2019-2024)
  • Table 152. Australia Thrombin, by End User USD Million (2019-2024)
  • Table 153. Rest of Asia-Pacific Thrombin, by Type USD Million (2019-2024)
  • Table 154. Rest of Asia-Pacific Thrombin, by Dosage Form USD Million (2019-2024)
  • Table 155. Rest of Asia-Pacific Thrombin, by End User USD Million (2019-2024)
  • Table 156. Europe Thrombin, by Country USD Million (2019-2024)
  • Table 157. Europe Thrombin, by Type USD Million (2019-2024)
  • Table 158. Europe Thrombin, by Dosage Form USD Million (2019-2024)
  • Table 159. Europe Thrombin, by End User USD Million (2019-2024)
  • Table 160. Germany Thrombin, by Type USD Million (2019-2024)
  • Table 161. Germany Thrombin, by Dosage Form USD Million (2019-2024)
  • Table 162. Germany Thrombin, by End User USD Million (2019-2024)
  • Table 163. France Thrombin, by Type USD Million (2019-2024)
  • Table 164. France Thrombin, by Dosage Form USD Million (2019-2024)
  • Table 165. France Thrombin, by End User USD Million (2019-2024)
  • Table 166. Italy Thrombin, by Type USD Million (2019-2024)
  • Table 167. Italy Thrombin, by Dosage Form USD Million (2019-2024)
  • Table 168. Italy Thrombin, by End User USD Million (2019-2024)
  • Table 169. United Kingdom Thrombin, by Type USD Million (2019-2024)
  • Table 170. United Kingdom Thrombin, by Dosage Form USD Million (2019-2024)
  • Table 171. United Kingdom Thrombin, by End User USD Million (2019-2024)
  • Table 172. Netherlands Thrombin, by Type USD Million (2019-2024)
  • Table 173. Netherlands Thrombin, by Dosage Form USD Million (2019-2024)
  • Table 174. Netherlands Thrombin, by End User USD Million (2019-2024)
  • Table 175. Rest of Europe Thrombin, by Type USD Million (2019-2024)
  • Table 176. Rest of Europe Thrombin, by Dosage Form USD Million (2019-2024)
  • Table 177. Rest of Europe Thrombin, by End User USD Million (2019-2024)
  • Table 178. MEA Thrombin, by Country USD Million (2019-2024)
  • Table 179. MEA Thrombin, by Type USD Million (2019-2024)
  • Table 180. MEA Thrombin, by Dosage Form USD Million (2019-2024)
  • Table 181. MEA Thrombin, by End User USD Million (2019-2024)
  • Table 182. Middle East Thrombin, by Type USD Million (2019-2024)
  • Table 183. Middle East Thrombin, by Dosage Form USD Million (2019-2024)
  • Table 184. Middle East Thrombin, by End User USD Million (2019-2024)
  • Table 185. Africa Thrombin, by Type USD Million (2019-2024)
  • Table 186. Africa Thrombin, by Dosage Form USD Million (2019-2024)
  • Table 187. Africa Thrombin, by End User USD Million (2019-2024)
  • Table 188. North America Thrombin, by Country USD Million (2019-2024)
  • Table 189. North America Thrombin, by Type USD Million (2019-2024)
  • Table 190. North America Thrombin, by Dosage Form USD Million (2019-2024)
  • Table 191. North America Thrombin, by End User USD Million (2019-2024)
  • Table 192. United States Thrombin, by Type USD Million (2019-2024)
  • Table 193. United States Thrombin, by Dosage Form USD Million (2019-2024)
  • Table 194. United States Thrombin, by End User USD Million (2019-2024)
  • Table 195. Canada Thrombin, by Type USD Million (2019-2024)
  • Table 196. Canada Thrombin, by Dosage Form USD Million (2019-2024)
  • Table 197. Canada Thrombin, by End User USD Million (2019-2024)
  • Table 198. Mexico Thrombin, by Type USD Million (2019-2024)
  • Table 199. Mexico Thrombin, by Dosage Form USD Million (2019-2024)
  • Table 200. Mexico Thrombin, by End User USD Million (2019-2024)
  • Table 201. Thrombin: by Type(USD/Units)
  • Table 202. Research Programs/Design for This Report
  • Table 203. Key Data Information from Secondary Sources
  • Table 204. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Thrombin: by Type USD Million (2013-2018)
  • Figure 5. Global Thrombin: by Dosage Form USD Million (2013-2018)
  • Figure 6. Global Thrombin: by End User USD Million (2013-2018)
  • Figure 7. South America Thrombin Share (%), by Country
  • Figure 8. Asia Pacific Thrombin Share (%), by Country
  • Figure 9. Europe Thrombin Share (%), by Country
  • Figure 10. MEA Thrombin Share (%), by Country
  • Figure 11. North America Thrombin Share (%), by Country
  • Figure 12. Global Thrombin: by Type USD/Units (2013-2018)
  • Figure 13. Global Thrombin share by Players 2018 (%)
  • Figure 14. Global Thrombin share by Players (Top 3) 2018(%)
  • Figure 15. Global Thrombin share by Players (Top 5) 2018(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 18. Pfizer (United States) Revenue: by Geography 2018
  • Figure 19. Johnson & Johnson Servicess, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Johnson & Johnson Servicess, Inc. (United States) Revenue: by Geography 2018
  • Figure 21. Octapharma AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 22. Octapharma AG (Switzerland) Revenue: by Geography 2018
  • Figure 23. Baxter International Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 24. Baxter International Inc. (United States) Revenue: by Geography 2018
  • Figure 25. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 26. Bayer AG (Germany) Revenue: by Geography 2018
  • Figure 27. CSL Limited (Australia) Revenue, Net Income and Gross profit
  • Figure 28. CSL Limited (Australia) Revenue: by Geography 2018
  • Figure 29. Grifols, S.A. (Spain) Revenue, Net Income and Gross profit
  • Figure 30. Grifols, S.A. (Spain) Revenue: by Geography 2018
  • Figure 31. GE Healthcare (United States) Revenue, Net Income and Gross profit
  • Figure 32. GE Healthcare (United States) Revenue: by Geography 2018
  • Figure 33. Hualan Biological (China) Revenue, Net Income and Gross profit
  • Figure 34. Hualan Biological (China) Revenue: by Geography 2018
  • Figure 35. Global Thrombin: by Type USD Million (2019-2024)
  • Figure 36. Global Thrombin: by Dosage Form USD Million (2019-2024)
  • Figure 37. Global Thrombin: by End User USD Million (2019-2024)
  • Figure 38. South America Thrombin Share (%), by Country
  • Figure 39. Asia Pacific Thrombin Share (%), by Country
  • Figure 40. Europe Thrombin Share (%), by Country
  • Figure 41. MEA Thrombin Share (%), by Country
  • Figure 42. North America Thrombin Share (%), by Country
  • Figure 43. Global Thrombin: by Type USD/Units (2019-2024)
Some of the key companies/manufacturers profiled in the report
  • Pfizer (United States)
  • Johnson & Johnson Servicess, Inc. (United States)
  • Octapharma AG (Switzerland)
  • Baxter International Inc. (United States)
  • Bayer AG (Germany)
  • CSL Limited (Australia)
  • Grifols, S.A. (Spain)
  • GE Healthcare (United States)
  • Hualan Biological (China)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation